Overview

Who the company is, and how Q3 compared with what Q2 guided

Aug 5 → Nov 3, 2026
NASDAQ: MIRMFoster City, CaliforniaCommercial stage
Mirum Pharmaceuticals
A rare-disease company with four approved medicines, mostly for rare liver conditions. Its late-stage pipeline is led by brelovitug, an antibody for chronic hepatitis delta.
Therapeutic areasRare liver disease · Hepatitis delta · Rare bone disease (FOP) · Fragile X
Marketed medicinesLIVMARLI · Cholbam · Ctexli · Atebrioz (launched Oct 2026)
Lead pipelineBrelovitug (Phase 3, BLA 1H 2027) · Volixibat (PSC, PBC) · MRM-3379
Modality and modelOral small molecules and antibodies · Direct product sales; Takeda partner in Japan

Analyst read

Q2 → Q3 2026
In short
Every 2026 date guided in the Q2 update was met. The one open item sits with the FDA.
Clinical delivery
Both brelovitug Phase 3 trials, the Atebrioz FDA decision and the EXPAND readout landed when Q2 said they would.
Commercial momentum
Sales grew again and full-year guidance went up for a second quarter running. Atebrioz launched in October.
Spending and cash
Higher R&D widened the operating loss, but operating cash use stayed small. Cash fell mainly on a note buyback.
The one to watch
Volixibat in PSC: the 1H 2027 filing plan stands, with no word on the FDA's Q2 call for a Phase 3 trial.

Guided next, as of the Q3 filing

Nov 3
Q4 2026First quarter of Atebrioz sales
Q1 2027Volixibat VANTAGE Phase 2b topline (PBC)
1H 2027Brelovitug BLA; possible US launch Q4 2027
1H 2027LIVMARLI sNDA · volixibat NDA · Atebrioz sNDA
2H 2027AZURE-2 and AZURE-3 topline

Net product sales and guidance

US$ M
Filing or financialGuided in Q2, deliveredNew since Q2Open questionGuided, not yet due
Program Q2 2026 view Q3 2026 view Date Status

Selected item

click a row

Brelovitug Phase 3 readouts

guided in Q2 · combined endpoint at Week 24

How to read the trials

Endpoint. Virologic response plus normal liver enzymes (ALT) at Week 24.

Control. Both AZURE trials used a delayed-treatment arm, not placebo. That arm started treatment at Week 24 in AZURE-1 and Week 12 in AZURE-4.

Drug. Brelovitug is a fully human monoclonal antibody that binds hepatitis B surface antigen, given under the skin weekly or every four weeks.

Next. BLA planned for 1H 2027. AZURE-2 and AZURE-3 topline in 2H 2027.

All readouts since the Q2 filing

Program changes, Q2 view → Q3 view

What it tells us